Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.60 |
| ▸ | MC4R | P32245 | 1/20 | 0.57 |
| ▸ | CHKA | P35790 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14661526 | 0.84 | HRH3 (0.60) | HRH3MC4RCHKANPC1TP53 | |
| SCHEMBL14661636 | 0.84 | HRH3 (0.60) | HRH3MC4RCHKANPC1TP53 | |
| SCHEMBL1482500 | 0.84 | HRH3 (0.60) | HRH3MC4RCHKAFAAH | |
| SCHEMBL29809149 | 0.84 | HRH3 (0.60) | HRH3MC4RCHKAFAAH | |
| SCHEMBL31721210 | 0.84 | HRH3 (0.60) | HRH3MC4RCHKANPC1TP53 | |
| SCHEMBL18945566 | 0.83 | HRH3 (0.66) | HRH3MC4RCHKANPC1TP53 | |
| SCHEMBL13535291 | 0.83 | MC4R (0.74) | HRH3MC4RCHKANPC1TP53 | |
| SCHEMBL6409204 | 0.81 | NCF1 (0.60) | HRH3NPC1TP53RAB9ACA2 | |
| SCHEMBL2324448 | 0.81 | SIGMAR1 (0.57) | HRH3SIGMAR1FAAH | |
| SCHEMBL1978437 | 0.80 | LMNA (0.61) | HRH3MC4RCHKANPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858898-B1 | HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA SA (FR) | 2009-08-26 | — | — | EP | disclosed |
| EP-1858898-A1 | HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE | Aventis Pharma S.A. (FR) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006092510-A1 | HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA S.A. (FR) | 2006-09-08 | — | — | WO | disclosed |
| US-20050222098-A1 | Regulation of meiosis | NOVO NORDISK A/S (DK) | 2005-10-06 | — | — | US | disclosed |
| EP-0767798-B1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK AS (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-20030004148-A1 | Regulation of meiosis | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222098-A1 | Regulation of meiosis | ALPG, MNS1, BUB1B | HRH3 3595/4885MC4R 4207/4885CHKA 1903/4885 |
| US-20030004148-A1 | Regulation of meiosis | ALPG, MNS1, BUB1B | HRH3 3595/4885MC4R 4207/4885CHKA 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.